To evaluate mechanisms of lethality following EGFR inhibition, we began by profiling EGFR inhibitor sensitivity in a panel of EGFR-mutant and EGFR wild-type NSCLC cell lines. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.